Option chain shows key data for HCW Biologics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for HCW Biologics.

HCW Biologics (NASDAQ:HCWB) Stock, Option Chain

HCW Biologics

HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.

Palantir,Technologies,Japan,Logo,,Tokyo,,Japan,2024,Sep.15

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AREB

AZTR

BCTX

EVAX

HCWB

ILMN

IVVD

KAPA

PDLB

PLTR

REBN

TNXP

UOKA

XPEV

ZONE

Why Palantir Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket

Crude Oil and Petroleum Trade in the Crosshairs

Earnings

Equities

Eurozone

Commodities

Intraday Update

GHRS

NSSC

Crude Oil Moves Higher; Owens &amp; Minor Shares Plummet

Improving Clinical Trials

HCW Biologics shares are trading higher on Monday after the company announced clearance from the Food and Drug Administration  for its Phase 1 trial of HCW9302.

What&#39;s Going On With HCW Biologics Stock Monday?

HCW Biologics Inc

Press Releases

HCW Biologics Reports Third Quarter 2024 Financial Results and Business Highlights

HCW Biologics and WY Biotech Announce License Agreement  for Immunotherapeutic Product Candidate

Spotlight on Undervalued Nasdaq Stocks: HCWB, CRDL, NIVF, SINT, APLM – A Must-Watch This Week!

IPOs

HCW Biologics Announces Pricing of $6.9 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under NASDAQ Rules

HCW Biologics Inc. Received NASDAQ Staff Determination Letter

HCW Biologics' Founder and CEO to Address Opportunities and Challenges in Biomanufacturing for Cell and Gene Therapies During J.P. Morgan Week in San Francisco on January 15, 2025

Health Care

HCW Biologics Granted FDA Clearance to Evaluate One of the Company's Lead Product Candidates in a First-In-Human Phase 1 Clinical Trial

HCW Biologics Granted Extension by the Nasdaq Hearings Panel to Regain Compliance with Continued Listing Requirements

HCW Biologics Reports Fourth Quarter and Fiscal Year 2024 Business Highlights and Financial Results

HCW Biologics Announces 1-for-40 Reverse Stock Split

APLM

CRDL

NIVF

SINT

Acurx Pharmaceuticals, Inc. - Common Stock

Acurx Pharmaceuticals

Ainos

Apollomics Inc. - Class A Ordinary Shares

Apollomics

Aptorum Group Limited - Class A Ordinary Shares

Aptorum Gr

Aprea Therapeutics

Brainstorm Cell Therapeutics Inc. - Common Stock

Brainstorm Cell

BioXcel Therapeutics, Inc. - Common Stock

BioXcel Therapeutics

Carisma Therapeutics, Inc. - Common Stock

CARISMA Therapeutics

Creative Medical Technology Holdings, Inc. - Common Stock

Creative Medical Tech

Channel Therapeutics Corporation Common Stock

Channel Therapeutics

Cyclerion Therapeutics, Inc. - Common Stock

Cyclerion Therapeutics

Dogwood Therapeutics, Inc. - Common Stock

Dogwood Therapeutics

GT Biopharma

Indaptus Therapeutics, Inc. - Common Stock

Indaptus Therapeutics

Intensity Therapeutics, Inc. - Common Stock

Intensity Therapeutics

Lipella Pharmaceuticals Inc. - Common Stock

Lipella Pharmaceuticals

MetaVia

Mainz Biomed

Phio Pharmaceuticals Corp. - Common Stock

Phio Pharma

PharmaCyte Biotech

TransCode Therapeutics, Inc. - Common Stock

TransCode Therapeutics

Silexion Therapeutics Corp - Ordinary Shares

Silexion Therapeutics

Soligenix

Turnstone Biologics

XTL Biopharmaceuticals Ltd. - American Depositary Shares

XTL Biopharmaceuticals

EF Hutton

JonesTrading

Comments

HCW Biologics

HCW Biologics (HCWB) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell